Partnerships in the introduction of new routine vaccines in Bangladesh: evidence from a prospective process evaluation.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
26 09 2022
Historique:
entrez: 27 9 2022
pubmed: 28 9 2022
medline: 30 9 2022
Statut: epublish

Résumé

To assess the contribution of partners in the introduction of two new vaccines concurrently: pneumococcal 10-valent conjugate vaccine (PCV-10) and inactivated polio vaccine (IPV) into the routine Expanded Programme on Immunization (EPI) in Bangladesh. We conducted a prospective process evaluation that included the theory of change development, root cause analysis and in-depth investigation. As part of process tracking, we reviewed relevant documents, observed trainers' and vaccinators' training and key stakeholder meetings. We analysed the data thematically. We purposively selected eight Nineteen national key informants were interviewed and 16 frontline health workers were invited to the group discussions considering their involvement in the vaccine introduction process. The EPI experienced several challenges during the joint introduction of PCV-10 and IPV, such as frequent changes in the vaccine introduction schedule, delays in budget allocation, vaccine supply shortage and higher wastage rates of IPV. EPI addressed these challenges in collaboration with its partners, that is, the World Health Organization (WHO) and United Nations Children's Fund (UNICEF), who provided technical assistance to develop a training curriculum and communication materials and enhanced demand generation at the community level. In addition, the WHO conducted a country readiness assessment for PCV-10, and UNICEF supported vaccine shipment. Other government ministries, City Corporations and municipalities also supported the EPI. The partnership among the EPI stakeholders effectively addressed various operational challenges during the joint introduction of PCV-10 and IPV helped strengthen Bangladesh's immunisation systems. These accomplishments are attributed to several factors that should be supported and strengthened for future vaccine introductions in Bangladesh and other low and-middle countries.

Identifiants

pubmed: 36167397
pii: bmjopen-2022-061742
doi: 10.1136/bmjopen-2022-061742
pmc: PMC9516160
doi:

Substances chimiques

Pneumococcal Vaccines 0
Poliovirus Vaccine, Inactivated 0
Vaccines, Conjugate 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e061742

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Lancet. 2007 Feb 3;369(9559):389-96
pubmed: 17276779
J Health Popul Nutr. 2008 Sep;26(3):295-310
pubmed: 18831226
Lancet Infect Dis. 2010 Nov;10(11):778-90
pubmed: 20961813
Lancet. 2009 Sep 12;374(9693):893-902
pubmed: 19748398
BMC Public Health. 2019 Jul 10;19(1):925
pubmed: 31291922
J Infect Dis. 2017 Jul 1;216(suppl_1):S52-S56
pubmed: 28838169
J Infect Dis. 2011 Jul;204 Suppl 1:S82-9
pubmed: 21666218
J Health Popul Nutr. 2013 Jun;31(2):211-7
pubmed: 23930339
Vaccine. 2004 Oct 22;22(31-32):4203-14
pubmed: 15474710
J Infect Dis. 2011 Jul;204 Suppl 1:S90-7
pubmed: 21666219
Am J Public Health. 2005 May;95(5):800-7
pubmed: 15855455
Hum Vaccin. 2011 Oct;7(10):1077-82
pubmed: 21941096
Health Policy Plan. 2012 May;27 Suppl 2:ii5-16
pubmed: 22513732
BMC Infect Dis. 2010 Sep 03;10:260
pubmed: 20815900
Bull World Health Organ. 2008 May;86(5):408-16
pubmed: 18545744
Trop Med Infect Dis. 2018 Jun 25;3(3):
pubmed: 30274468
BMC Public Health. 2011 Apr 13;11 Suppl 3:S26
pubmed: 21501444
Health Policy Plan. 2012 May;27 Suppl 2:ii27-38
pubmed: 22513730
Glob Health Sci Pract. 2014 Dec 10;2(4):381-94
pubmed: 25611473

Auteurs

Sharmin Khan Luies (SK)

Infectious Diseases Division, icddr,b, 68 Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka 1212, Bangladesh sharminkhan.luies@gmail.com.

Tahmina Sultana (T)

Research Program, Bangladesh Institute of Governance and Management, Dhaka, Bangladesh.

Ashwin Budden (A)

D'EVA Consulting, Washington, District of Columbia, USA.

Mohammad Asaduzzaman (M)

SanMarkS at iDE (International Development Enterprises), iDE Bangladesh, Dhaka, Bangladesh.

Md Billal Hossain (MB)

Department of Sociology, Shahjalal University of Science and Technology, Sylhet, Bangladesh.

Matthew Kelly (M)

National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.

Darren Gray (D)

National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.

Md Jasim Uddin (MJ)

Health Systems and Population Studies Division, icddr,b, 68 Shaheed Tajuddin Ahmed Sarani, Mohakhal, Dhaka 1212, Bangladesh.

Haribondhu Sarma (H)

National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH